Biohit Oyj

Share Issue/Capital Change • Dec 9, 2021

Biohit Oyj Board of Directors decided on new option scheme

Biohit Oyj Board of Directors decided on new option scheme

Biohit Oyj Stock Exchange Release December 9, 2021 14:00 EET

Biohit Oyj’s Board of Directors has, based on authorization of Biohit Oyj’s
General Shareholders’’ Meeting on September 9, 2020, decided on new option
scheme to Group’s key personnel. Option rights are part of the Biohit Oyj’s and
its group of companies’ motivation and reward system and therefore there is a
weighty financial reason for the scheme.

The maximum total number of the option rights to be granted is 880.000. The
option rights entitle to subscribe a maximum total amount of 880.000 class B-
shares of Biohit Oyj. Option rights are issued gratuitously.

Of the granted option rights:

i. 88.000 of the option rights are called as ”I 2021A”;
ii. 88.000 of the option rights are called as ”I 2021B”;
iii. 88.000 of the option rights are called as ”I 2021C”;
iv. 88.000 of the option rights are called as ”I 2021D”;
v. 88.000 of the option rights are called as ”I 2021E”;
vi. 110.000 of the option rights are called as ”II 2021A”;
vii. 110.000 of the option rights are called as ”II 2021B”;
viii. 110.000 of the option rights are called as ”II 2021C”; and
ix. 110.000 of the option rights are called as ”II 2021D”.

Share subscription prices for shares subscribed based on the option rights are:

· for option right classes I 2021A, I 2021B, I 2021C, I 2021D and I 2021E 1,00
euro; and
· for option right classes II 2021A, II 2021B, II 2021C and II 2021D 2,00
euros

The Board has determined the subscription prices of options and shares based on
current value of the shares, estimation of the future value of the shares and
the objective to engage and provide incentive to option holders. Right to
execute the option is conditional to reaching of the financial targets that are
defined separately.

Receivers of the option rights:

Päivi Siltala, CEO, total number of option rights 200.000

Jussi Hahtela, CFO, total number of option rights 200.000

Ilari Patrakka, Sales and Marketing Director, total number of option rights
80.000

Suvi Elomaa, Production Director, total number of option rights 80.000

Minna Mäki, R&D Director, total number of option rights 80.000

Daniela Söderström, Quality and Registration Director, total number of option
rights 80.000

Tapani Tiusanen, Technology Director, total number of option rights 80.000

Graham Johnson, Managing Director, Biohit UK, total number of option rights
80.000

Share subscription periods for shares subscribed based on the option rights are:

i. for option right class I 2021A during 1 March 2023 – 1 March 2028;
ii. for option right class I 2021B during 1 March 2024 – 1 March 2028;
iii. for option right class I 2021C during 1 March 2025 – 1 March 2028;
iv. for option right class I 2021D during 1 March 2026 – 1 March 2028;
v. for option right class I 2021E during 1 March 2027 – 1 March 2028;
vi. for option right class II 2021A during 1 March 2024 – 1 March 2028;
vii. for option right class II 2021B during 1 March 2025 – 1 March 2028;
viii. for option right class II 2021C during 1 March 2026 – 1 March 2028; and
ix. for option right class II 2021D during 1 March 2027 – 1 March 2028.

Biohit Oyj

Board of Directors

Further information

Eero Lehti, Chairman, tel. +358 9 773 861

Attachments: